<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Plakous Therapeutics</title>
    <link>https://www.biospace.com/employer/3076411/plakous-therapeutics</link>
    <description>Plakous Therapeutics</description>
    <language>en-US</language>
    <lastBuildDate>Fri, 19 Jun 2020 13:56:03 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/3076411/plakous-therapeutics.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Plakous Therapeutics Receives Rare Pediatric Disease and Orphan Drug Designations for Protego-PD™ for the Prevention of Necrotizing Enterocolitis</title>
      <link>https://www.biospace.com/plakous-therapeutics-receives-rare-pediatric-disease-and-orphan-drug-designations-for-protego-pd-for-the-prevention-of-necrotizing-enterocolitis</link>
      <description>Plakous Therapeutics, Inc. has been granted orphan drug and rare pediatric disease designations for its human placental extract, Protego-PD™, for the prevention of necrotizing enterocolitis (NEC) in early preterm infants.</description>
      <pubDate>Fri, 19 Jun 2020 13:56:03 GMT</pubDate>
      <guid>https://www.biospace.com/plakous-therapeutics-receives-rare-pediatric-disease-and-orphan-drug-designations-for-protego-pd-for-the-prevention-of-necrotizing-enterocolitis</guid>
    </item>
    <item>
      <title>Plakous Therapeutics Awarded $1.7 Million Fast-Track SBIR Grant from NIH to Develop Therapies for Necrotizing Enterocolitis</title>
      <link>https://www.biospace.com/plakous-therapeutics-awarded-1-7-million-fast-track-sbir-grant-from-nih-to-develop-therapies-for-necrotizing-enterocolitis</link>
      <description>Plakous Therapeutics, Inc. received a notice of award for a Phase I-II Fast-Track Small Business Innovation Research (SBIR) grant providing up to $1,725,000 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health (NIH). The grant will assist Plakous' developme</description>
      <pubDate>Tue, 07 Jul 2020 14:16:07 GMT</pubDate>
      <guid>https://www.biospace.com/plakous-therapeutics-awarded-1-7-million-fast-track-sbir-grant-from-nih-to-develop-therapies-for-necrotizing-enterocolitis</guid>
    </item>
    <item>
      <title>Plakous Therapeutics extends research through agreement with Mayo Clinic</title>
      <link>https://www.biospace.com/plakous-therapeutics-extends-research-through-agreement-with-mayo-clinic</link>
      <description>Plakous Therapeutics, Inc. announced that it has signed a know-how license agreement with Mayo Clinic. The multi-year agreement will focus on understanding the results of a natural history study of the factors associated with necrotizing enterocolitis (NEC), a rare disease affecting premature babies. Plakous has received Orphan</description>
      <pubDate>Tue, 25 Aug 2020 17:46:06 GMT</pubDate>
      <guid>https://www.biospace.com/plakous-therapeutics-extends-research-through-agreement-with-mayo-clinic</guid>
    </item>
    <item>
      <title>Plakous Therapeutics Awarded Phase II SBIR Grant from NIH to Continue Development of Therapies for Necrotizing Enterocolitis</title>
      <link>https://www.biospace.com/plakous-therapeutics-awarded-phase-ii-sbir-grant-from-nih-to-continue-development-of-therapies-for-necrotizing-enterocolitis</link>
      <description>Plakous Therapeutics, Inc. received a notice of award for Phase II of its Small Business Innovation Research (SBIR) grant providing $1.5 million from the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health (NIH).</description>
      <pubDate>Tue, 10 Aug 2021 15:46:04 GMT</pubDate>
      <guid>https://www.biospace.com/plakous-therapeutics-awarded-phase-ii-sbir-grant-from-nih-to-continue-development-of-therapies-for-necrotizing-enterocolitis</guid>
    </item>
    <item>
      <title>Plakous Therapeutics Announces New Funding to Support Development of Therapies for Necrotizing Enterocolitis</title>
      <link>https://www.biospace.com/plakous-therapeutics-announces-new-funding-to-support-development-of-therapies-for-necrotizing-enterocolitis</link>
      <description>Plakous Therapeutics, Inc. today announced it is has received more than $300,000 in funding from the North Carolina Biotechnology Center (NCBiotech).</description>
      <pubDate>Tue, 05 Jul 2022 15:56:04 GMT</pubDate>
      <guid>https://www.biospace.com/plakous-therapeutics-announces-new-funding-to-support-development-of-therapies-for-necrotizing-enterocolitis</guid>
    </item>
  </channel>
</rss>
